MONTREAL, Sept. 8 /CNW Telbec/ - Haemacure Corporation (TSX:HAE), a
specialty bio-therapeutics company, announces that its Chairman and CEO, Mr.
Joseph Galli, will present at the Rodman & Renshaw 11th Annual Healthcare
Conference on September 9, 2009 at 2:00 p.m. at the New York Palace Hotel in
The presentation will be live by webcast at
http://www.wsw.com/webcast/rrshq15/hae.to. Please visit the site at least five
minutes prior to start time for instructions.
Haemacure Corporation is a specialty biotherapeutics company developing
high-value human plasma-derived protein products for commercialization.
Haemacure's research and development effort is driven by its proprietary
plasma protein extraction technology to develop next-generation products,
including surgical haemostats. Haemacure's proprietary, lead product candidate
is a fibrin sealant in late-stage clinical trials. Haemacure's proprietary,
second product candidate is thrombin, a component of its fibrin sealant, now
in preclinical stage. Follow-on development will focus on the use of fibrin
sealant in aesthetics, adhesion prevention, combination with biomaterials,
drug delivery, regenerative medecine, skin graft fixation for burn injuries,
and wound healing.
Certain of the statements contained in this news release are
forward-looking statements. Such statements, based as they are on the current
expectations of management, inherently involve numerous risks and
uncertainties, known and unknown. Some examples of known risks are: the impact
of general economic conditions, general conditions in the biotech industry,
changes in the regulatory environment in the jurisdictions in which Haemacure
does business, stock market volatility, fluctuations in costs, and changes to
the competitive environment due to consolidation or otherwise. Consequently,
actual future results may differ materially from the anticipated results
expressed in the forward-looking statements. Haemacure disclaims any intention
or obligation to update these statements.
For further information:
For further information: Joseph Galli, Chairman and CEO, Haemacure
Corporation, (514) 990-7074, email@example.com; Gilles Lemieux, Secretary,
Haemacure Corporation, (514) 282-3350 ext. 22, firstname.lastname@example.org;